Profile data is unavailable for this security.
About the company
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
- Revenue in USD (TTM)242.00k
- Net income in USD-19.09m
- Incorporated2012
- Employees15.00
- LocationOrganovo Holdings IncSuite 100, 11555 Sorrento Valley RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 224-1000
- Fax+1 (302) 636-5454
- Websitehttps://organovo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guardion Health Sciences Inc | 12.06m | -5.12m | 12.24m | 9.00 | -- | 3.58 | -- | 1.01 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
Marizyme Inc | 645.81k | -65.35m | 12.26m | 11.00 | -- | -- | -- | 18.98 | -1.43 | -1.43 | 0.0142 | -0.0354 | 0.0213 | 1.56 | 8.72 | 58,710.00 | -215.30 | -59.02 | -351.53 | -64.47 | 70.87 | 70.38 | -10,118.60 | -9,435.92 | 0.0458 | -0.6565 | 1.36 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 12.39m | 233.00 | 0.0831 | 0.0013 | 3.21 | 0.1751 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
ELEVAI Labs Inc | 2.18m | -4.62m | 12.47m | 18.00 | -- | 4.60 | -- | 5.71 | -0.2665 | -0.2665 | 0.126 | 0.1435 | -- | -- | -- | 121,351.70 | -- | -- | -- | -- | 67.84 | -- | -211.42 | -- | 1.80 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
Plus Therapeutics Inc (USA) | 6.08m | -11.77m | 12.61m | 20.00 | -- | -- | -- | 2.07 | -3.19 | -3.19 | 1.67 | -1.13 | 0.5724 | -- | -- | 304,200.00 | -110.75 | -59.18 | -- | -133.04 | -- | -- | -193.49 | -470.45 | -- | -- | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
GlucoTrack Inc | 0.00 | -8.74m | 12.71m | 6.00 | -- | 33.02 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
Organovo Holdings Inc | 242.00k | -19.09m | 12.77m | 15.00 | -- | 1.56 | -- | 52.78 | -2.17 | -2.17 | 0.0275 | 0.6283 | 0.0143 | -- | 4.44 | 12,100.00 | -112.40 | -51.24 | -123.59 | -54.90 | -- | -- | -7,886.36 | -1,269.78 | -- | -- | 0.00 | -- | -75.33 | -39.60 | -50.76 | -- | 5.99 | -- |
Shineco Inc | 5.62m | -14.34m | 12.89m | 87.00 | -- | 0.3582 | -- | 2.29 | -3.98 | -2.32 | 1.36 | 5.58 | 0.0664 | 0.48 | 1.45 | 64,633.68 | -19.79 | -12.77 | -38.28 | -16.84 | 12.77 | 25.88 | -298.09 | -102.06 | 0.4842 | -8.14 | 0.3908 | -- | -- | -58.35 | -33.86 | -- | -- | -- |
Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 12.94m | 12.00 | -- | 0.3709 | 5.57 | 0.809 | -1.60 | -1.60 | 1.21 | 1.33 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Nexgel Inc | 4.74m | -3.20m | 12.95m | 19.00 | -- | 2.71 | -- | 2.74 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Actavia Life Sciences Inc | 0.00 | -406.65k | 13.04m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
Dominari Holdings Inc | 3.41m | -24.56m | 13.12m | 26.00 | -- | 0.2752 | -- | 3.85 | -4.64 | -4.64 | 0.6305 | 8.03 | 0.0539 | -- | 0.8023 | 131,000.00 | -38.88 | -26.82 | -39.93 | -27.45 | -- | -- | -721.11 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
Inhibikase Therapeutics Inc | 195.98k | -19.20m | 13.28m | 8.00 | -- | 1.76 | -- | 67.75 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Cell MedX Corp | 70.00 | -96.91k | 13.38m | 0.00 | -- | -- | -- | 191,080.50 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.40m | 46.00 | -- | 0.5715 | -- | 0.3274 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Check Cap Ltd | 0.00 | -17.57m | 13.42m | 85.00 | -- | 0.5669 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 353.61k | 3.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 142.21k | 1.25% |
Renaissance Technologies LLCas of 31 Mar 2024 | 97.79k | 0.86% |
Geode Capital Management LLCas of 31 Mar 2024 | 74.91k | 0.66% |
Citadel Securities LLCas of 31 Mar 2024 | 46.38k | 0.41% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 38.78k | 0.34% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 27.83k | 0.24% |
XTX Markets LLCas of 31 Mar 2024 | 22.63k | 0.20% |
Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 19.82k | 0.17% |
UBS Securities LLCas of 31 Mar 2024 | 15.07k | 0.13% |